KMT2A and leukemia: These data suggest DOT1L to be a powerfuloncogene driving breast tumorigenesis in tumour initiation and progression.Recently, several potent catalytic inhibitors of DOT1L that cause tumour regressionin MLL-rearranged leukaemia have been discovered and are undergoing clinicaltrials9, 38.